Opdivo (nivolumab) Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The opdivo (nivolumab) market size has grown strongly in recent years. It will grow from $8.34 million in 2025 to $9.01 million in 2026 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to approval of pd-1 inhibitors, rising global cancer burden, limitations of chemotherapy, strong clinical trial outcomes, oncologist adoption of immunotherapy.

The opdivo (nivolumab) market size is expected to see strong growth in the next few years. It will grow to $12.13 million in 2030 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to expansion into new oncology indications, growth of combination therapy protocols, increasing biomarker based patient selection, rising cancer diagnosis rates, increased oncology healthcare spending. Major trends in the forecast period include expanding use of immune checkpoint inhibitors, rising adoption of combination immunotherapy regimens, growth in pd-1 based cancer treatments, increased use across multiple cancer indications, focus on long term survival outcomes.

The increasing incidence of non-small cell lung cancer (NSCLC) is expected to drive the growth of the Opdivo (nivolumab) market in the coming years. NSCLC is the most common type of lung cancer, accounting for approximately 85% of all lung cancer cases. The rising incidence of NSCLC is primarily due to factors such as smoking, exposure to environmental pollutants, genetic mutations, and a family history of cancer. Opdivo works by blocking the PD-1 receptor on immune cells, enhancing the body’s immune response to recognize and attack cancer cells. For example, in 2024, the American Cancer Society, a US-based health organization, reported 234,580 new lung cancer cases in the United States, with 80% being NSCLC. This marks an increase compared to 2023, when 238,340 people were diagnosed with lung cancer. Therefore, the rising incidence of NSCLC is driving the Opdivo (nivolumab) market.

Leading companies in the Opdivo (nivolumab) market are focusing on developing advanced combination therapies to improve treatment efficacy, overcome resistance, and expand applications across multiple cancer types. Combination therapy involves using Opdivo (nivolumab) alongside other agents, such as chemotherapy, to provide a more comprehensive approach for patients with advanced cancer. For instance, in October 2024, the US Food and Drug Administration approved Opdivo (nivolumab) in combination with platinum-doublet chemotherapy as a neoadjuvant treatment, followed by single-agent nivolumab as adjuvant therapy after surgery, for adults with resectable NSCLC without known EGFR or ALK mutations. This approval allows Opdivo to be administered both before and after surgery, enhancing therapeutic outcomes for eligible patients.

In June 2024, I-Mab, a US-based biotechnology company developing innovative cancer immunotherapies, entered a clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate the bispecific antibody givastomig. Through this partnership, I-Mab plans to assess its investigational Claudin 18.2 × 4-1BB bispecific antibody, givastomig, in combination with Opdivo (nivolumab) and standard chemotherapy regimens (FOLFOX or CAPOX) as a potential first-line treatment for patients with advanced Claudin 18.2-positive gastric and esophageal cancers. Bristol Myers Squibb, a US-based pharmaceutical company, manufactures Opdivo (nivolumab).

Major companies operating in the opdivo (nivolumab) market are Bristol-Myers Squibb, Ono Pharmaceutical.

North America was the largest region in the 0pdivo (nivolumab) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the opdivo (nivolumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the opdivo (nivolumab) market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have impacted the opdivo market by increasing costs related to imported biologic manufacturing inputs, monoclonal antibody processing equipment, and cold-chain logistics. These pressures are more visible in hospital oncology settings where biologics form a major cost component. Regions such as north america and europe experience pricing sensitivity due to biologic import reliance. At the same time, tariffs are encouraging regional biologics manufacturing investments. This is improving supply resilience and reducing long-term dependency on cross-border sourcing.

The opdivo (nivolumab) market research report is one of a series of new reports that provides opdivo (nivolumab) market statistics, including opdivo (nivolumab) industry global market size, regional shares, competitors with a opdivo (nivolumab) market share, detailed opdivo (nivolumab) market segments, market trends and opportunities, and any further data you may need to thrive in the opdivo (nivolumab) industry. This opdivo (nivolumab) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Opdivo (nivolumab) is a prescription drug classified as an immune checkpoint inhibitor that specifically targets programmed death-1 (PD-1) receptors. It is an immunotherapy used to treat various cancers by boosting the body’s immune system to recognize and destroy cancer cells.

The main forms of Opdivo (nivolumab) available in the market are 40 mg/4 ml, 100 mg/10 ml, and 240 mg/24 ml. The 40 mg/4 ml dose is a lower concentration intended for patients who require smaller doses, often used in specific treatment protocols or for lower-weight patients. The drug is available in various forms, including injections and solutions, and is used across demographics such as adults and pediatric patients. Its applications include melanoma, non-small cell lung cancer (NSCLC), malignant pleural mesothelioma, classical Hodgkin lymphoma (CHL), squamous cell carcinoma of the head and neck (SCCHN), renal cell carcinoma (RCC), and other cancers. End-users include hospitals, clinics, and other healthcare facilities.

The opdivo (nivolumab) market consists of sales of monotherapy and combination therapy. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.